{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:47:09Z","timestamp":1764510429915},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.leukres.2012.03.010","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T02:01:13Z","timestamp":1333591273000},"page":"813-814","source":"Crossref","is-referenced-by-count":9,"title":["Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: Who's afraid of the big bad wolf?"],"prefix":"10.1016","volume":"36","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2012.03.010_bib0005","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","article-title":"Prevalence and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999\u20132000","volume":"110","author":"Selvin","year":"2004","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.leukres.2012.03.010_bib0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.leukres.2012.03.010_bib0015","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2012.03.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2753.2753","article-title":"Nilotinib exerts direct effects on vascular endothelial cells and may act as a co-trigger of atherosclerosis in patients with Ph+ CML","volume":"118","author":"Hadzijusufovic","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.03.010_bib0025","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2757.2757","article-title":"Retrospective cohort analysis of peripheral arterial occlusive disease (PAOD) events in patients with chronic myeloid leukemia in chronic phase (CML-CP)","volume":"118","author":"Giles","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2012.03.010_bib0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ahj.2011.05.012","article-title":"Current therapeutics and practical management strategies for pulmonary arterial hypertension","volume":"162","author":"Agarwal","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.leukres.2012.03.010_bib0035","unstructured":"EMEA: Sprycel-Scientific discussion. European Public Assessment Report (EPAR 2011)."},{"issue":"25","key":"10.1016\/j.leukres.2012.03.010_bib0040","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.leukres.2012.03.010_bib0045","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.leukres.2008.09.026","article-title":"Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia","volume":"33","author":"Rasheed","year":"2009","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.leukres.2012.03.010_bib0050","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bmt.2008.415","article-title":"Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient","volume":"43","author":"Mattei","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.leukres.2012.03.010_bib0055","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1183\/09031936.00154210","article-title":"Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia","volume":"38","author":"Dumitrescu","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.leukres.2012.03.010_bib0060","first-page":"11","article-title":"Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?","volume":"23","author":"Hennigs","year":"2011","journal-title":"BMC Pulm Med"},{"issue":"81","key":"10.1016\/j.leukres.2012.03.010_bib0065","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.leukres.2011.08.007","article-title":"Reversible pulmonary arterial hypertension likely related to long-term, low dose dasatinib treatment for chronic myeloid leukemia","volume":"36","author":"Orlandi","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2012.03.010_bib0070","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612001324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612001324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T12:15:13Z","timestamp":1593951313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612001324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0145212612001324"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.03.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}